OREANDA-NEWS. GE Healthcare Life Sciences continues to invest in Uppsala. The company signs a two-year collaboration agreement with Uppsala BIO. The goal is to find technologies and equipment that support the production and processing of biopharmaceuticals in the future. “Although we are a large, international company, it is rare that we form this type of active technology scouting partnerships”, says Jonas ?str?m, Head of Strategic technologies for BioProcess, GE Healthcare Life Sciences.

“The objective of this collaboration is to find new ideas and promising start-up companies, and to establish partnerships that will benefit both parties. The role of Uppsala BIO is to find researchers or smaller companies that need the support that an international company of GE's caliber has. We have worked with the sector for nearly 15 years and want to find new ways, so that there would be more life science companies that can establish themselves, grow and take their products to the market”, says Erik Forsberg, Managing Director of Uppsala BIO.

The agreement with GE Healthcare runs for two years - how the collaboration works will vary case by case.

“It might be a researcher with an exciting idea or a promising product from a more established small business that would benefit from getting some insight or financing from GE on how to bring the product closer to commercialization”, says Erik Forsberg. “We have early-stage projects in our BIO-X program and that can be valid for this collaboration as well, but we will also look wider, not just in the region.”

“All major life science companies are looking at different ways to expand their technology base including external collaborations to create the right conditions for the creation of new products. Uppsala BIO's long experience in reviewing, selecting and supporting promising projects has been an important criterion to form this partnership”, continues Jonas ?str?m.

GE Healthcare operates in over 100 countries and it is one of the leading suppliers of equipment that is being used for protein analysis and for the development and manufacturing of biopharmaceuticals. The company is also the largest private employer in Uppsala with around 1,200 employees, of those around 400 work in research and development. Recently the production facility received a large investment that will significantly increase the production capacity in Uppsala over the next three years.